U
IMGN

UBS’s Immunogen Inc IMGN Stock Holding History

UBS’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$323K Sell
30,523
-25,678
-46% -$290K ﹤0.01% 4701
2014
Q2 		$666K Sell
56,201
-852
-1% -$10.7K ﹤0.01% 3946
2014
Q1 		$852K Buy
57,053
+11,434
+25% +$180K ﹤0.01% 3654
2013
Q4 		$670K Buy
45,619
+18,183
+66% +$279K ﹤0.01% 4001
2013
Q3 		$467K Buy
27,436
+4,129
+18% +$72.6K ﹤0.01% 4219
2013
Q2 		$387K Buy
+23,307
New +$378K ﹤0.01% 4350

Other funds holding IMGN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

UBS's IMGN Position: Q3 2014 in Review

UBS reduced its Immunogen Inc (IMGN) stake by 46% in Q3 2014, selling an estimated $290K and leaving 30,523 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #4701.

UBS first reported a position in IMGN in Q2 2013 and has held it in 6 quarters since. The position peaked at $852K in Q1 2014. 141 funds tracked by Wall St. Rank hold IMGN as of Q3 2014.

  • UBS held 30,523 shares of Immunogen Inc worth $323K as of Q3 2014.
  • UBS sold 25,678 Immunogen Inc shares in Q3 2014, an estimated $290K.
  • Immunogen Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4701 holding.
  • UBS first reported a position in Immunogen Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Immunogen Inc position peaked at $852K in Q1 2014.
  • 141 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.